Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial

Stroke

Volumn 37, Issue 12, 2006, Pages 2970-2978

  Lees, Kennedy R ^a   Davalos, Antonio ^b   Davis, Stephen M ^c   Diener, Hans Christoph ^d   Grotta, James ^e   Lyden, Patrick ^f   Shuaib, Ashfaq ^g   Ashwood, Tim ^h   Hardemark, Hans Goran ^h   Wasiewski, Warren ^k   Emeribe, Ugochi ⁱ   Zivin, Justin A ^j  

^a WESTERN INFIRMARY   (United Kingdom)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF ALBERTA   (Canada)

^h ASTRAZENECA R AND D   (Sweden)

ⁱ ASTRAZENECA   (United Kingdom)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k NONE

more..

Author keywords

Acute care; Drug trials; Free radicals; Ischemia; Neuroprotection; NXY 059

Indexed keywords

ALTEPLASE; DISUFENTON SODIUM; PLACEBO;

ARTICLE; BARTHEL INDEX; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISABILITY; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROPROTECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS;

EID: 33845430453     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000249410.91473.44     Document Type: Article

References (19)

1. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr., Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004 363(9411):768-74.
2. IMAGES Study Group. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet. 2004;363:439-445.
3. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW; Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
4. Lees KR, Sharma AK, Barer D, Ford GA, Kostulas V, Cheng YF, Odergren T. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke. 2001;32:675-680.
5. Lees KR, Barer D, Ford GA, Hacke W, Kostulas V, Sharma AK, Odergren T; SA-NXY-0004 Investigators. Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke. 2003;34:482-487.
6. Green AR, Ashwood T, Odergren T, Jackson DM. Nitrones as neuroprotective agents in cerebral ischemia with particular reference to NXY-059. Pharmacol Ther. 2003;100:195-214.
7. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864-870.
8. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31:103-115.
9. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, Van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
10. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md Med J. 1965;14:61-65.
11. Stokes ME, Davis CS, Koch GG. Categorical Data Analysis using the SAS system, 2nd edition, Cary, NC: SAS Institute Inc; 2000.
12. Chi GYH. Multiple testing: multiple comparisons and multiple endpoints. Drug Information J. 1998;32: 1347S-1362S
13. Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M, Orgogozo JM, Whitehead J. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet. 2000;355:1949-1954.
14. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
15. Young FB, Lees KR, Weir CJ. Strengthening acute stroke trials through optimal use of disability endpoints. Stroke. 2003;34:2676-2680.
16. Fisher M; for the Stroke Therapy Academic Industry Roundtable. Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry Roundtable. Stroke. 2005;36:1808-1813.
17. Committee for Proprietary Medicinal Products (CPMP). Points to consider on clinical investigation of medicinal products for the treatment of acute stroke. The European Agency for the Evaluation of Medicinal Products. London. 2001 CPMP/EWP/560/98.
18. Young FB, Weir CJ, Lees KR; GAIN International Trial Steering Committee and Investigators. Comparison of the National Institutes of Health Stroke Scale with disability outcome measures in acute stroke trials. Stroke. 2005;36:2187-2192.
19. Weimar C, Kurth T, Kraywinkel K, Wagner M, Busse O, Haberl RL, Diener HC; German Stroke Data Bank Collaborators. Assessment of functioning and disability after ischemic stroke. Stroke. 2002;33:2053-2059.